A recent study reveals that people who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end traditional lifestyle plans.
Findings released in a leading medical journal shows that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"People purchasing such drugs should be aware of the risk of rapid rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
That rate of regain suggests a return to starting weight within about 18 months.
Comparing Treatments
The analysis, which looked at 37 of trials involving thousands of participants, compared the results of these new drugs with conventional dieting.
The team note that individuals who lose weight through diet and exercise usually see a more gradual weight regain—approximately 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Experts believe the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the body to produce less of its own natural hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making binge eating far more likely."
A Lifelong Issue?
Health authorities advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy is often ongoing.
This view is echoed by pharmaceutical companies, who state that the results "underscore the chronic character of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have discontinued the medication report a sudden resurgence of appetite.
"I experienced a switch flipping and you become extremely hungry," recalled a patient.
This challenge is compounded if patients have not adopted permanent dietary or behavioural changes during therapy.
Widespread Use
Figures suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a standalone cure and lasting health benefits relies on integrated behavioural management.
